

Syed Anwer Hussain

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7924301/publications.pdf>

Version: 2024-02-01

112
papers

7,388
citations

126907

33
h-index

54911

84
g-index

114
all docs

114
docs citations

114
times ranked

11129
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. <i>Nature Communications</i> , 2022, 13, 1878.	12.8	3
2	Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 650-658.	10.7	16
3	Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial. <i>European Urology</i> , 2022, 82, 273-279.	1.9	29
4	Perioperative Treatment in Muscle-invasive Bladder Cancer: Analysis of Secondary Endpoints in a Randomized Trial Comparing Gemcitabine and Cisplatin Versus Dose-dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin. <i>European Urology</i> , 2021, 79, 222-224.	1.9	2
5	Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>European Urology</i> , 2021, 79, 307-315.	1.9	20
6	Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). <i>Clinical Cancer Research</i> , 2021, 27, 1882-1892.	7.0	15
7	Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. <i>Lancet Oncology</i> , The, 2021, 22, 246-255.	10.7	73
8	Urological cancer patients receiving treatment during COVID-19: a single-centre perspective. <i>British Journal of Cancer</i> , 2021, 124, 1513-1515.	6.4	2
9	A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2021, 80, 712-723.	1.9	43
10	Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes. <i>European Urology</i> , 2021, 79, 621-632.	1.9	77
11	Bladder cancer: shedding light on the most promising investigational drugs in clinical trials. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 837-855.	4.1	14
12	Reply to Santhanam Sundar and Paul Symonds™ Letter to the Editor re: Syed A. Hussain, Nuria Porta, Emma Hall, et al. Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>Eur Urol</i> 2021;79:307-15. <i>European Urology</i> , 2021, 80, e51-e52.	1.9	0
13	Concurrent use of nivolumab and radiotherapy for patients with metastatic non-small cell lung cancer and renal cell carcinoma with oligometastatic disease progression on nivolumab. <i>Molecular and Clinical Oncology</i> , 2021, 15, 214.	1.0	1
14	Rare case of chemotherapy-refractory metastatic vaginal squamous cell carcinoma with complete response to concurrent pembrolizumab and radiotherapy- case report and literature review. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100878.	0.6	3
15	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. <i>European Urology Oncology</i> , 2020, 3, 671-679.	5.4	11
16	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	10.7	61
17	Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>European Urology</i> , 2020, 77, 260-268.	1.9	58
18	Occupational bladder cancer: A cross section survey of previous employments, tasks and exposures matched to cancer phenotypes. <i>PLoS ONE</i> , 2020, 15, e0239338.	2.5	14

#	ARTICLE	IF	CITATIONS
19	The Impact of Centralised Services on Metric Reflecting High-quality Performance: Outcomes from 1110 Consecutive Radical Cystectomies at a Single Centre. <i>European Urology Focus</i> , 2020, 7, 554-565.	3.1	7
20	Reply to Wei Liu, Xiaoping Liu, Sheng Li's Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>Eur Urol</i> 2020;77:260-8. <i>European Urology</i> , 2020, 77, e156-e157.	1.9	0
21	ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. <i>Trials</i> , 2020, 21, 344.	1.6	7
22	Phase II randomized placebo-controlled neoadjuvant trial of nintedanib or placebo with gemcitabine and cisplatin in locally advanced muscle invasive bladder cancer (NEO-BLADE).. <i>Journal of Clinical Oncology</i> , 2020, 38, 438-438.	1.6	10
23	Title is missing!. , 2020, 15, e0239338.		0
24	Title is missing!. , 2020, 15, e0239338.		0
25	Title is missing!. , 2020, 15, e0239338.		0
26	Title is missing!. , 2020, 15, e0239338.		0
27	Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer. <i>European Urology</i> , 2019, 76, 604-606.	1.9	4
28	Vinflunine in the treatment of relapsed metastatic urothelial cancer: A systematic review and meta-analysis of real-world series. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 80-87.	4.4	3
29	Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. <i>European Urology</i> , 2018, 73, 462-468.	1.9	36
30	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 748-757.	13.7	1,142
31	Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. <i>European Urology Focus</i> , 2018, 4, 937-945.	3.1	7
32	Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e161-e167.	1.9	3
33	From Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma. <i>European Urology Oncology</i> , 2018, 1, 486-500.	5.4	35
34	Therapeutics discovery: From bench to first in-human trials*. <i>Biomedical Reports</i> , 2018, 8, 275-282.	2.0	0
35	Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747). <i>BJU International</i> , 2017, 119, 522-529.	2.5	18
36	Towards better models and mechanistic biomarkers for drug-induced gastrointestinal injury. , 2017, 172, 181-194.		19

#	ARTICLE	IF	CITATIONS
37	VICTOR: Vinflunine in advanced metastatic transitional cell carcinoma of the urothelium: A retrospective analysis of the use of vinflunine in multi-centre real life setting as second line chemotherapy through Free of Charge Programme for patients in the UK and Ireland. <i>International Journal of Oncology</i> , 2017, 50, 768-772.	3.3	10
38	The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). <i>British Journal of Cancer</i> , 2017, 116, 649-657.	6.4	9
39	Gene expression profiling in bladder cancer identifies potential therapeutic targets. <i>International Journal of Oncology</i> , 2017, 50, 1147-1159.	3.3	17
40	Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 48-55.	1.6	165
41	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 2266-2277.	13.7	153
42	Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1770-1777.	1.6	27
43	Phase I/II trial of cetuximab with 5-fluorouracil and mitomycin C concurrent with radiotherapy in patients with muscle invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4527-4527.	1.6	1
44	BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 280-280.	1.6	15
45	Inhibitor SBF126 suppresses the malignant progression of castration-resistant PC3-M cells by competitively binding to oncogenic FABP5. <i>Oncotarget</i> , 2017, 8, 31041-31056.	1.8	32
46	Fatty acid activated PPAR γ promotes tumorigenicity of prostate cancer cells by up regulating <i>VEGF</i> via PPAR responsive elements of the promoter. <i>Oncotarget</i> , 2016, 7, 9322-9339.	1.8	68
47	Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers. <i>Current Treatment Options in Oncology</i> , 2016, 17, 15.	3.0	10
48	Cisplatin- Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 331-340.	1.9	12
49	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. <i>Journal of Clinical Oncology</i> , 2016, 34, 3005-3013.	1.6	202
50	Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both. <i>JAMA Oncology</i> , 2016, 2, 493.	7.1	78
51	A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2016, 69, 450-456.	1.9	80
52	The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance. <i>Oncotarget</i> , 2016, 7, 82783-82797.	1.8	30
53	Bladder reconstruction: The past, present and future. <i>Oncology Letters</i> , 2015, 10, 3-10.	1.8	41
54	A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 87-95.	2.3	40

#	ARTICLE	IF	CITATIONS
55	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 178-184.	1.9	15
56	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	27.0	1,796
57	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. <i>Cancer</i> , 2015, 121, 2586-2593.	4.1	155
58	The international normalized ratio does not reflect bleeding risk in esophageal variceal hemorrhage. <i>Saudi Journal of Gastroenterology</i> , 2015, 21, 254.	1.1	12
59	Low vitamin D level is an independent predictor of poor outcomes in <i>Clostridium difficile</i> -associated diarrhea. <i>Therapeutic Advances in Gastroenterology</i> , 2014, 7, 14-19.	3.2	20
60	The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 144-153.	2.5	217
61	The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 806-814.	1.6	78
62	Pooled Analysis of Phase II Trials Evaluating Weekly or Conventional Cisplatin as First-Line Therapy for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 316-320.	1.9	5
63	Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004). <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 261-269.	0.8	115
64	Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom. <i>British Journal of Cancer</i> , 2013, 109, 888-890.	6.4	16
65	Pillcam ESO [®] is more accurate than clinical scoring systems in risk stratifying emergency room patients with acute upper gastrointestinal bleeding. <i>Therapeutic Advances in Gastroenterology</i> , 2013, 6, 193-198.	3.2	29
66	Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma. <i>Biologics: Targets and Therapy</i> , 2013, 7, 39.	3.2	3
67	A Multidisciplinary Approach in Muscle-Invasive Disease: Novel Chemotherapy Combinations and Targets in Chemoradiation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, , 200-206.	3.8	0
68	A Multidisciplinary Approach in Muscle-Invasive Disease: Novel Chemotherapy Combinations and Targets in Chemoradiation. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 200-206.	3.8	1
69	Ketamine-induced Biliary Dilatation. <i>Journal of Addiction Medicine</i> , 2012, 6, 89-91.	2.6	17
70	Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 1477-1488.	27.0	788
71	A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. <i>Oncology Letters</i> , 2012, 3, 855-859.	1.8	49
72	Changing angles: Successful treatment of superior mesenteric artery syndrome with double-balloon enteroscopy-assisted direct feeding jejunostomy. <i>Digestive Endoscopy</i> , 2012, 24, 482-482.	2.3	2

#	ARTICLE	IF	CITATIONS
73	UNIQUE USAGE OF A PARTIALLY COVERED METAL STENT FOR DRAINAGE OF A PANCREATIC PSEUDOCYST VIA ENDOSONOGRAPHY&GUIDED TRANSCYSTGASTROSTOMY. Digestive Endoscopy, 2012, 24, 185-187.	2.3	3
74	The Successful Treatment of Chronic Cholecystitis with SpyGlass Cholangioscopy-Assisted Gallbladder Drainage and Irrigation through Self- Expandable Metal Stents. Gut and Liver, 2012, 6, 136-138.	2.9	12
75	Active surveillance for prostate cancer: Scottish experience.. Journal of Clinical Oncology, 2012, 30, 167-167.	1.6	0
76	Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2012, 30, 308-308.	1.6	0
77	Biology of Germ Cell Tumors. Hematology/Oncology Clinics of North America, 2011, 25, 457-471.	2.2	6
78	Live View Video Capsule Endoscopy Enables Risk Stratification of Patients with Acute Upper GI Bleeding in the Emergency Room: A Pilot Study. Digestive Diseases and Sciences, 2011, 56, 786-791.	2.3	43
79	Assessment of high&throughput high&resolution MALDI&TOF&MS of urinary peptides for the detection of muscle&invasive bladder cancer. Proteomics - Clinical Applications, 2011, 5, 493-503.	1.6	29
80	The West Midlands Bladder Cancer Prognosis Programme: rationale and design. BJU International, 2010, 105, 784-788.	2.5	52
81	Outcomes of critically ill patients with acute kidney injury and end-stage renal disease requiring renal replacement therapy: a case-control study. Nephrology Dialysis Transplantation, 2009, 24, 2290-2290.	0.7	0
82	Identification of Small Bowel Diverticula with Double-Balloon Enteroscopy Following Non-diagnostic Capsule Endoscopy. Digestive Diseases and Sciences, 2009, 54, 2296-2297.	2.3	5
83	Outcome among patients with acute renal failure needing continuous renal replacement therapy: A single center study. Hemodialysis International, 2009, 13, 205-214.	0.9	15
84	Chemotherapy related encephalopathy in a patient with Stage IV cervical carcinoma treated with cisplatin and 5-fluorouracil: a case report. Cases Journal, 2009, 2, 8526.	0.4	7
85	Multifocal Granular Cell Tumor Presenting as an Esophageal Stricture. Journal of Gastrointestinal Cancer, 2008, 39, 107-113.	1.3	15
86	Biology of testicular germ cell tumors. Expert Review of Anticancer Therapy, 2008, 8, 1659-1673.	2.4	19
87	Management of metastatic germ cell tumors. Expert Review of Anticancer Therapy, 2008, 8, 771-784.	2.4	18
88	Genomics and Pharmacogenomics in the Management of Breast Cancer. Current Pharmacogenomics and Personalized Medicine, 2008, 6, 45-55.	0.2	0
89	Access to Kidney Transplantation among Patients Insured by the United States Department of Veterans Affairs. Journal of the American Society of Nephrology: JASN, 2007, 18, 2592-2599.	6.1	24
90	Signal Transduction Therapy: Challenges to Clinical Trial Design. Current Signal Transduction Therapy, 2007, 2, 21-30.	0.5	1

#	ARTICLE	IF	CITATIONS
91	Molecularly Targeted Therapeutics for Breast Cancer. <i>BioDrugs</i> , 2007, 21, 215-224.	4.6	15
92	Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. <i>British Journal of Cancer</i> , 2007, 96, 104-109.	6.4	184
93	Reply: Randomised studies with translational end points are required to further elucidate the prognostic and predictive value of CA IX. <i>British Journal of Cancer</i> , 2007, 96, 1310-1310.	6.4	1
94	BK virus infection after renal transplantation. <i>Current Opinion in Organ Transplantation</i> , 2006, 11, 413-417.	1.6	0
95	Phosphorus-enriched hemodialysis during pregnancy: Two case reports. <i>Hemodialysis International</i> , 2005, 9, 147-152.	0.9	23
96	BK virus nephritis: Risk factors, timing, and outcome in renal transplant recipients. <i>Kidney International</i> , 2005, 68, 1834-1839.	5.2	205
97	Molecular pathways in bladder cancer: Part 1. <i>BJU International</i> , 2005, 95, 485-490.	2.5	33
98	Molecular pathways in bladder cancer: Part 2. <i>BJU International</i> , 2005, 95, 491-496.	2.5	27
99	Management of muscle invasive bladder cancer? British approaches to organ conservation. <i>Seminars in Radiation Oncology</i> , 2005, 15, 19-27.	2.2	12
100	Molecular markers in bladder cancer. <i>Seminars in Radiation Oncology</i> , 2005, 15, 3-9.	2.2	21
101	Role of chemotherapy in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 1095-1110.	2.4	10
102	Gene- and immunotherapy for hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 507-523.	3.1	16
103	Endocrine therapy and other targeted therapies for metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 1179-1195.	2.4	9
104	A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. <i>British Journal of Cancer</i> , 2004, 91, 844-849.	6.4	98
105	Systemic therapies for hepatocellular carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1555-1568.	4.1	48
106	Successful treatment of radiation nephropathy with angiotensin II blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 190-193.	0.8	50
107	The systemic treatment of advanced and metastatic bladder cancer. <i>Lancet Oncology</i> , The, 2003, 4, 489-497.	10.7	100
108	Proapoptotic genes BAX and CD40L are predictors of survival in transitional cell carcinoma of the bladder. <i>British Journal of Cancer</i> , 2003, 88, 586-592.	6.4	42

#	ARTICLE	IF	CITATIONS
109	Organ preservation strategies in bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2002, 2, 641-651.	2.4	11
110	Rapid kidney allograft failure in patients with polyoma virus nephritis with prior treatment with antilymphocyte agents. <i>Clinical Transplantation</i> , 2002, 16, 43-47.	1.6	37
111	Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. <i>Annals of Oncology</i> , 2001, 12, 245-248.	1.2	133
112	A phase II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. <i>Annals of Oncology</i> , 2001, 12, 929-935.	1.2	23